Mira Pharmaceuticals Reports Significant Asset Growth and Ongoing Losses in Q3 2025

Mira Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a significant increase in total assets and stockholders' equity compared to the previous fiscal period. As of September 30, 2025, the company’s total assets reached $7.6 million, up from $2.9 million at the end of 2024. This increase was primarily driven by the acquisition of SKNY Pharmaceuticals, which contributed $4.7 million in marketable equity securities to the balance sheet. Stockholders' equity also saw a substantial rise, climbing to $7.5 million from $2.2 million, reflecting the issuance of common stock as part of the acquisition.

Despite the growth in assets and equity, Mira Pharmaceuticals reported no revenues for the three and nine months ended September 30, 2025. The company incurred a net loss of $1.1 million for the third quarter, a decrease from a loss of $2.0 million in the same period last year. For the nine months ended September 30, 2025, the net loss was approximately $4.5 million, down from $5.5 million in the prior year. The reduction in losses was attributed to decreased operating costs, particularly in research and development expenses, which fell to $0.4 million in Q3 2025 from $1.0 million in Q3 2024.

Operationally, Mira Pharmaceuticals has made significant strides in its clinical development programs. The company is advancing its lead drug candidates, Ketamir-2 and MIRA-55, with ongoing clinical trials and preclinical studies. The acquisition of SKNY Pharmaceuticals on September 29, 2025, is expected to enhance the company’s pipeline with SKNY-1, a preclinical drug candidate targeting metabolic and behavioral disorders. The company has also reported positive preclinical results for both Ketamir-2 and MIRA-55, indicating their potential efficacy in treating various conditions.

Mira Pharmaceuticals continues to face challenges related to its liquidity and funding requirements. The company has historically operated at a loss and has relied on external financing to support its operations. As of September 30, 2025, the company had approximately $2.6 million in cash, which is insufficient to cover its operational needs for the next 12 months. Management has indicated that securing additional capital through equity offerings and strategic partnerships will be critical for funding ongoing clinical trials and operational expenses. The company has a shelf registration statement in place to facilitate future capital raises, but there is no guarantee that it will be able to secure the necessary funding on favorable terms.